Bioresorbable Scaffold Articles & Analysis
14 news found
“The funding we have secured will allow REVA to move forward with our pivotal clinical trial to support FDA approval of our MOTIV peripheral vascular scaffold as well as to obtain FDA clearance of our TyroSphere bioresorbable embolic bead ...
Yoshinobu Onuma, MD, PhD is a leading expert in the field of bioresorbable scaffolds. He also has extensive expertise in quantative coronary angiography (2-dimensional, 3-dimensional and bifurcation-dedicated), intravascular imaging, Syntax Score and metallic stents. ...
Following the successful completion of the R&D project in 30th September 2016 (supported by a Smart award from the Innovate UK (TSB), Arterius has recently been awarded further funding from the Biomedical Catalyst-Early Stage programme to conduct the In-vitro and In-vivo GLP Evaluation of the Novel Bioresorbable Coronary Scaffolds; ArterioSorb. ArterioSorb ...
The talk was part of the “BRS: Evolving Technologies and Applications” session, also featuring presentations about Elixir’s DESolve scaffold, Abbott’s ABSORB clinical data, Biotronik’s BIOSOLVE-II trial data, and REVA Medical’s Fantom scaffold. Prof Serruys presented the latest bench testing development results of the ...
ArterioSorb has been shown to show decreased acute thrombus formation compared to thicker strut bioresorbable scaffolds (BRS) in an in-vitro model. Shengjie Lu PhD, of the National Heart Research Institute and National Heart Centre Singapore, presented a moderated poster at TCT 2017 in Denver, showing the impact of BRS strut thickness on the formation of ...
(“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the presentation of the 6- month clinical outcomes data from a post market study of the Company’s MOTIV Below The Knee (BTK) scaffold. ...
The trial evaluated the safety and performance of the Company’s Fantom sirolimus-eluting bioresorbable coronary scaffold in over 240 patients outside the United States. ...
Arterius Limited, a Leeds-based, UK company developing innovative medical devices with a focus on next generation bioresorbable coronary and peripheral stents, has announced that it has appointed Steve Parker as Chief Executive Officer. ...
Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study. ...
Clinical studies have shown that a DES prevents positive adaptive remodeling,5 inhibits vessel compliance and dilation in response to the body’s changing blood flow needs,6,7 and causes vessel straightening, which has been associated with increased MACE.8 The DynamX Bioadaptor is a metal implant with a drug-eluting bioresorbable polymer coating that supports the coronary ...
The DynamX Bioadaptor is a metal implant with a drug-eluting bioresorbable polymer coating that supports the coronary artery during healing, with radial strength similar to DES. ...
The DynamX Bioadaptor is a metal implant with a drug-eluting bioresorbable polymer coating, having a radial strength similar to DES. Over six months, the polymer coating dissolves, uncaging the bioadaptor and freeing the artery to move with the natural expansion and contraction of the artery, unlike DES. ...
The DynamX Bioadaptor is a metal implant with a drug-eluting bioresorbable polymer coating that supports the coronary artery during healing, with radial strength similar to DES. ...
The randomized substudy PROSPECT ABSORB, which was simultaneously published in the Journal of the American College of Cardiology (JACC), showed treatment of high-risk vulnerable plaques with a bioresorbable vascular scaffold (BVS) was safe and substantially associated with favorable long-term clinical outcomes compared to guideline-directed medical therapy (GDMT) ...